Lianxin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lianxin Wang has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Yanming Xie
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, China
9 shared publications - Mengmeng Wang
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
6 shared publications - Chunquan Sun
Tsinghua University Yuquan Hospital (Tsinghua University Hospital of Integrative Traditional Chinese and Western Medicine), Beijing, China
4 shared publications - Hongyan Zhang
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
4 shared publications - Lan Cheng
Beijing Puren Hospital, Beijing, China
4 shared publications - Liran Ma
Beijing GULOU Hospital of Traditional Chinese Medicine, Beijing, China
4 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Wolters Kluwer Health in Guidelines and Standards of Chinese Medicine
- Vol. 4 (3) , 207-212
Leveraging multibiomarkers for precision diagnosis of coronary heart disease with phlegm and blood stasis syndrome: a real-world observational study protocol
Objective: To assess the diagnostic value of multiple biomarkers, including blood lipid, coagulation, and inflammatory markers, both individually and in combination, for assisting the precision diagnosis of coronary heart disease with phlegm and blood stasis syndrome (CHD-PBSS) in a real-world observational study, thereby providing a scientific basis for future research on the precision diagnosis of CHD-PBSS. Methods: This is a multicenter, real-world observational study designed to recruit 360 patients aged 35 to 70 years with chronic stable CHD from several medical institutions, including Beijing First Hospital of Integrated Chinese and Western Medicine, Yichang Hospital of Traditional Chinese Medicine (TCM), and Huanggang Hospital of TCM. Patients with CHD-PBSS were assigned to the PBSS group ( n = 180), whereas those with CHD but without PBSS (CHD-NPBSS) were assigned to the NPBSS group (n=180). We compared the levels of blood lipid, coagulation, and inflammatory biomarkers between the 2 groups and subsequently evaluated the diagnostic accuracy of these biomarkers, both individually and in combination, for identifying PBSS in patients with CHD. Discussion: The precision diagnosis of PBSS, a critical syndrome in CHD, is crucial for developing effective prevention and management strategies within the framework of TCM. This study aims to identify clinical diagnostic biomarkers of CHD-PBSS through real-world clinical trials, providing a theoretical basis for achieving accurate TCM syndrome diagnosis. However, the observational design has inherent limitations, as it only offers basic demographic information and does not allow for causal inference. In addition, the complexity of TCM syndromes and the subjectivity of clinicians’ judgements may introduce information and selection biases, potentially affecting the accuracy of the results.
- 27 July 2026
- Published by Wolters Kluwer Health in Guidelines and Standards of Chinese Medicine
- Vol. 4 (3) , 207-212
Open AccessLeveraging multibiomarkers for precision diagnosis of coronary heart disease with phlegm and blood stasis syndrome: a real-world observational study protocol
Objective: To assess the diagnostic value of multiple biomarkers, including blood lipid, coagulation, and inflammatory markers, both individually and in combination, for assisting the precision diagnosis of coronary heart disease with phlegm and blood stasis syndrome (CHD-PBSS) in a real-world observational study, thereby providing a scientific basis for future research on the precision diagnosis of CHD-PBSS. Methods: This is a multicenter, real-world observational study designed to recruit 360 patients aged 35 to 70 years with chronic stable CHD from several medical institutions, including Beijing First Hospital of Integrated Chinese and Western Medicine, Yichang Hospital of Traditional Chinese Medicine (TCM), and Huanggang Hospital of TCM. Patients with CHD-PBSS were assigned to the PBSS group ( n = 180), whereas those with CHD but without PBSS (CHD-NPBSS) were assigned to the NPBSS group (n=180). We compared the levels of blood lipid, coagulation, and inflammatory biomarkers between the 2 groups and subsequently evaluated the diagnostic accuracy of these biomarkers, both individually and in combination, for identifying PBSS in patients with CHD. Discussion: The precision diagnosis of PBSS, a critical syndrome in CHD, is crucial for developing effective prevention and management strategies within the framework of TCM. This study aims to identify clinical diagnostic biomarkers of CHD-PBSS through real-world clinical trials, providing a theoretical basis for achieving accurate TCM syndrome diagnosis. However, the observational design has inherent limitations, as it only offers basic demographic information and does not allow for causal inference. In addition, the complexity of TCM syndromes and the subjectivity of clinicians’ judgements may introduce information and selection biases, potentially affecting the accuracy of the results.
- Open Access
- 21 April 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e84867
Correction: Real-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study
[This corrects the article DOI: 10.2196/84803.].
- 21 April 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e84867
Open AccessCorrection: Real-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study
[This corrects the article DOI: 10.2196/84803.].
- Open Access
- 25 March 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e84803
Real-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study
Background: Menopausal syndrome (MPS) results from declining ovarian function and estrogen fluctuations during the menopausal transition, typically presenting with vasomotor, psychological, and metabolic symptoms that impair quality of life. Current treatments, including hormone replacement therapy and nonhormonal medications, are limited by safety concerns and adverse effects. The Liuwei Dihuang (LWDH) pill, a classical traditional Chinese medicine formula, is widely used for kidney-yin deficiency and menopausal symptoms such as hot flashes, insomnia, depression, and anxiety. Preliminary studies suggest favorable efficacy and safety; however, robust real-world evidence, particularly in combination with conventional Western therapy, remains insufficient. Objective: This study aims to evaluate the real-world effectiveness and safety of LWDH in combination with conventional Western therapy for MPS. Methods: This prospective, multicenter, real-world, observational cohort study will be conducted at 8 centers in China from March 9, 2025, to December 2026. A total of 1000 patients with MPS in a real-time clinical setting will be allocated to either the exposure group (conventional therapy plus LWDH) or the nonexposure group (conventional therapy alone). The primary outcome is the change in the modified Kupperman Index. The secondary outcomes encompass changes in the Menopausal Quality of Life Scale, serum sex hormone levels, traditional Chinese medicine syndrome scores, and metabolic parameters. Metabolomics analyses will be conducted to explore potential mechanisms. Safety will be assessed by monitoring adverse events and clinically significant abnormalities in vital signs or laboratory parameters. Assessments will be conducted at baseline and at 2 and 4 weeks, with a subsequent 2-week follow-up. Propensity score–based inverse probability of treatment weighting will be applied to balance baseline covariates, and weighted regression models will be used for comparative analyses. Results: Participant recruitment and enrollment began in March 2025. It is expected that by December 2026, a total of 1000 participants will be recruited. At present, patient recruitment is ongoing, and preliminary organization and analysis of medical record data are underway. Blood sample collection for metabolomics analysis is also in progress. Final data collection is expected to be completed in March 2027. We expect to generate evidence to support clinical decision-making, with results anticipated to be published in esteemed, peer-reviewed health research journals by December 2027. Conclusions: This study will assess the clinical effectiveness, safety, and potential mechanisms of LWDH in the treatment of MPS in real-world settings, providing a scientific basis for its use in clinical practice. Trial Registration: ClinicalTrials.gov NCT06874738; https://clinicaltrials.gov/study/NCT06874738 International Registered Report Identifier (IRRID): DERR1-10.2196/84803
- 25 March 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e84803
Open AccessReal-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study
Background: Menopausal syndrome (MPS) results from declining ovarian function and estrogen fluctuations during the menopausal transition, typically presenting with vasomotor, psychological, and metabolic symptoms that impair quality of life. Current treatments, including hormone replacement therapy and nonhormonal medications, are limited by safety concerns and adverse effects. The Liuwei Dihuang (LWDH) pill, a classical traditional Chinese medicine formula, is widely used for kidney-yin deficiency and menopausal symptoms such as hot flashes, insomnia, depression, and anxiety. Preliminary studies suggest favorable efficacy and safety; however, robust real-world evidence, particularly in combination with conventional Western therapy, remains insufficient. Objective: This study aims to evaluate the real-world effectiveness and safety of LWDH in combination with conventional Western therapy for MPS. Methods: This prospective, multicenter, real-world, observational cohort study will be conducted at 8 centers in China from March 9, 2025, to December 2026. A total of 1000 patients with MPS in a real-time clinical setting will be allocated to either the exposure group (conventional therapy plus LWDH) or the nonexposure group (conventional therapy alone). The primary outcome is the change in the modified Kupperman Index. The secondary outcomes encompass changes in the Menopausal Quality of Life Scale, serum sex hormone levels, traditional Chinese medicine syndrome scores, and metabolic parameters. Metabolomics analyses will be conducted to explore potential mechanisms. Safety will be assessed by monitoring adverse events and clinically significant abnormalities in vital signs or laboratory parameters. Assessments will be conducted at baseline and at 2 and 4 weeks, with a subsequent 2-week follow-up. Propensity score–based inverse probability of treatment weighting will be applied to balance baseline covariates, and weighted regression models will be used for comparative analyses. Results: Participant recruitment and enrollment began in March 2025. It is expected that by December 2026, a total of 1000 participants will be recruited. At present, patient recruitment is ongoing, and preliminary organization and analysis of medical record data are underway. Blood sample collection for metabolomics analysis is also in progress. Final data collection is expected to be completed in March 2027. We expect to generate evidence to support clinical decision-making, with results anticipated to be published in esteemed, peer-reviewed health research journals by December 2027. Conclusions: This study will assess the clinical effectiveness, safety, and potential mechanisms of LWDH in the treatment of MPS in real-world settings, providing a scientific basis for its use in clinical practice. Trial Registration: ClinicalTrials.gov NCT06874738; https://clinicaltrials.gov/study/NCT06874738 International Registered Report Identifier (IRRID): DERR1-10.2196/84803
- Open Access
- 6 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (6) , e47612
Causality between noise pollution and Alzheimer disease: A Mendelian randomization analysis
The role of noise pollution as a risk factor for Alzheimer disease (AD) is unclear, with observational studies yielding conflicting results susceptible to confounding and reverse causality. To clarify this relationship, we performed a 2-sample Mendelian randomization (MR) study using summary statistics from large-scale genome-wide association studies of European populations. Genetically predicted daytime and evening noise exposure was used as an instrumental variable to assess a causal effect on AD risk. The primary analysis was conducted using the inverse-variance weighted method, with weighted median and MR-Egger methods as key sensitivity analyses. We assessed instrument validity and pleiotropy using the Cochran Q test, the MR-Egger intercept, and leave-one-out analysis. Our MR analysis found no evidence of a causal association between genetically predicted daytime noise (odds ratio [95% confidence interval] = 0.999 [0.993–1.006], P = .819) or evening noise (odds ratio [95% confidence interval] = 0.999 [0.993–1.005], P = .643) and the risk of AD. Sensitivity analyses were consistent, with no evidence of heterogeneity or directional pleiotropy. In conclusion, this study does not support a direct causal link between noise and AD. While our findings mitigate common observational biases, they do not preclude indirect mechanisms whereby noise may influence AD pathogenesis via established risk pathways, such as chronic sleep disruption and cardiovascular stress. Studies are needed to focus on disentangling these potential indirect effects.
- 6 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (6) , e47612
Open AccessCausality between noise pollution and Alzheimer disease: A Mendelian randomization analysis
The role of noise pollution as a risk factor for Alzheimer disease (AD) is unclear, with observational studies yielding conflicting results susceptible to confounding and reverse causality. To clarify this relationship, we performed a 2-sample Mendelian randomization (MR) study using summary statistics from large-scale genome-wide association studies of European populations. Genetically predicted daytime and evening noise exposure was used as an instrumental variable to assess a causal effect on AD risk. The primary analysis was conducted using the inverse-variance weighted method, with weighted median and MR-Egger methods as key sensitivity analyses. We assessed instrument validity and pleiotropy using the Cochran Q test, the MR-Egger intercept, and leave-one-out analysis. Our MR analysis found no evidence of a causal association between genetically predicted daytime noise (odds ratio [95% confidence interval] = 0.999 [0.993–1.006], P = .819) or evening noise (odds ratio [95% confidence interval] = 0.999 [0.993–1.005], P = .643) and the risk of AD. Sensitivity analyses were consistent, with no evidence of heterogeneity or directional pleiotropy. In conclusion, this study does not support a direct causal link between noise and AD. While our findings mitigate common observational biases, they do not preclude indirect mechanisms whereby noise may influence AD pathogenesis via established risk pathways, such as chronic sleep disruption and cardiovascular stress. Studies are needed to focus on disentangling these potential indirect effects.
- Open Access
- 25 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Real-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study (Preprint)
BACKGROUND Menopausal syndrome (MPS) results from declining ovarian function and estrogen fluctuations during the menopausal transition, typically presenting with vasomotor, psychological, and metabolic symptoms that impair quality of life. Current treatments, including hormone replacement therapy and nonhormonal medications, are limited by safety concerns and adverse effects. The Liuwei Dihuang (LWDH) pill, a classical traditional Chinese medicine formula, is widely used for kidney-yin deficiency and menopausal symptoms such as hot flashes, insomnia, depression, and anxiety. Preliminary studies suggest favorable efficacy and safety; however, robust real-world evidence, particularly in combination with conventional Western therapy, remains insufficient. OBJECTIVE This study aims to evaluate the real-world effectiveness and safety of LWDH in combination with conventional Western therapy for MPS. METHODS This prospective, multicenter, real-world, observational cohort study will be conducted at 8 centers in China from March 9, 2025, to December 2026. A total of 1000 patients with MPS in a real-time clinical setting will be allocated to either the exposure group (conventional therapy plus LWDH) or the nonexposure group (conventional therapy alone). The primary outcome is the change in the modified Kupperman Index. The secondary outcomes encompass changes in the Menopausal Quality of Life Scale, serum sex hormone levels, traditional Chinese medicine syndrome scores, and metabolic parameters. Metabolomics analyses will be conducted to explore potential mechanisms. Safety will be assessed by monitoring adverse events and clinically significant abnormalities in vital signs or laboratory parameters. Assessments will be conducted at baseline and at 2 and 4 weeks, with a subsequent 2-week follow-up. Propensity score–based inverse probability of treatment weighting will be applied to balance baseline covariates, and weighted regression models will be used for comparative analyses. RESULTS Participant recruitment and enrollment began in March 2025. It is expected that by December 2026, a total of 1000 participants will be recruited. At present, patient recruitment is ongoing, and preliminary organization and analysis of medical record data are underway. Blood sample collection for metabolomics analysis is also in progress. Final data collection is expected to be completed in March 2027. We expect to generate evidence to support clinical decision-making, with results anticipated to be published in esteemed, peer-reviewed health research journals by December 2027. CONCLUSIONS This study will assess the clinical effectiveness, safety, and potential mechanisms of LWDH in the treatment of MPS in real-world settings, providing a scientific basis for its use in clinical practice. CLINICALTRIAL ClinicalTrials.gov NCT06874738; https://clinicaltrials.gov/study/NCT06874738 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/84803
- 25 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessReal-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study (Preprint)
BACKGROUND Menopausal syndrome (MPS) results from declining ovarian function and estrogen fluctuations during the menopausal transition, typically presenting with vasomotor, psychological, and metabolic symptoms that impair quality of life. Current treatments, including hormone replacement therapy and nonhormonal medications, are limited by safety concerns and adverse effects. The Liuwei Dihuang (LWDH) pill, a classical traditional Chinese medicine formula, is widely used for kidney-yin deficiency and menopausal symptoms such as hot flashes, insomnia, depression, and anxiety. Preliminary studies suggest favorable efficacy and safety; however, robust real-world evidence, particularly in combination with conventional Western therapy, remains insufficient. OBJECTIVE This study aims to evaluate the real-world effectiveness and safety of LWDH in combination with conventional Western therapy for MPS. METHODS This prospective, multicenter, real-world, observational cohort study will be conducted at 8 centers in China from March 9, 2025, to December 2026. A total of 1000 patients with MPS in a real-time clinical setting will be allocated to either the exposure group (conventional therapy plus LWDH) or the nonexposure group (conventional therapy alone). The primary outcome is the change in the modified Kupperman Index. The secondary outcomes encompass changes in the Menopausal Quality of Life Scale, serum sex hormone levels, traditional Chinese medicine syndrome scores, and metabolic parameters. Metabolomics analyses will be conducted to explore potential mechanisms. Safety will be assessed by monitoring adverse events and clinically significant abnormalities in vital signs or laboratory parameters. Assessments will be conducted at baseline and at 2 and 4 weeks, with a subsequent 2-week follow-up. Propensity score–based inverse probability of treatment weighting will be applied to balance baseline covariates, and weighted regression models will be used for comparative analyses. RESULTS Participant recruitment and enrollment began in March 2025. It is expected that by December 2026, a total of 1000 participants will be recruited. At present, patient recruitment is ongoing, and preliminary organization and analysis of medical record data are underway. Blood sample collection for metabolomics analysis is also in progress. Final data collection is expected to be completed in March 2027. We expect to generate evidence to support clinical decision-making, with results anticipated to be published in esteemed, peer-reviewed health research journals by December 2027. CONCLUSIONS This study will assess the clinical effectiveness, safety, and potential mechanisms of LWDH in the treatment of MPS in real-world settings, providing a scientific basis for its use in clinical practice. CLINICALTRIAL ClinicalTrials.gov NCT06874738; https://clinicaltrials.gov/study/NCT06874738 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/84803
- Open Access
- 21 March 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e65789
Clinical Safety of Pudilan Xiaoyan Oral Liquid for the Treatment of Upper Respiratory Tract Infection in the Real World: Protocol for a Prospective, Observational, Registry Study
Background: Pudilan Xiaoyan oral liquid (PDL) is a proprietary Chinese medicine preparation widely used for upper respiratory tract infection, known for its significant therapeutic effects. However, the safety profiles reported in several observational studies vary, and these studies primarily focus on efficacy rather than specifically addressing safety concerns, thus representing inadequate safety monitoring. Objective: This study aimed to investigate the incidence of adverse drug reactions (ADRs) associated with PDL and explore the factors contributing to these reactions. Methods: The study is a prospective, observational, multicenter, hospital-based surveillance study. A total of 17 hospitals from China are involved. The study is expected to enroll a large sample of 10,000 patients aged between 18 and 80 years with upper respiratory tract infection who were prescribed PDL. The patients’ data, including demographics, medical history, diagnostic information, medication details, adverse events, and laboratory test results, will be monitored. The occurrence of ADRs will be recorded. The primary outcome is the incidence of ADR. Secondary outcomes are the ratio of patients whose body temperature return to the normal range (cases of body temperature normalization and the duration for achieving normal body temperature within a 3-day period will be documented) and changes in liver and kidney function (occurrence of drug-induced liver injury and acute kidney injury). Descriptive analyses will be performed for the primary and secondary outcomes. A cohort, nested, case-control study design will be used. If one patient has an ADR, then 4 patients without ADRs will be matched as the control group according to gender, age within 5 years, drug batch, and other factors, at a ratio of 1∶4 to compare the symptoms related to ADRs. The differences of ADR incidence among the possible influencing factors will be compared separately to find the factors with large differences. Then, synthetic minority oversampling technique and group least absolute shrinkage and selection operator methods will be used to identify factors influencing the occurrence of ADRs. Finally, propensity scoring methods will be used to control for confounding variables. The progress of each subcenter will be closely monitored, and the incidence of ADR will be systematically calculated. Furthermore, the characteristics and influencing factors of ADR will be analyzed, along with an investigation into its geographical distribution. Results: The study began on July 17, 2019. Due to the limited number of eligible patients, missed follow-ups, and the huge clinical burden caused by public health events in 2019, the final case will be enrolled on August 30, 2025. Conclusions: This study will obtain safety results of PDL in the real world and provide guidance on the clinical safety of traditional Chinese medicine formulations. Trial Registration: ClinicalTrials.gov NCT04031651; https://clinicaltrials.gov/study/NCT04031651 International Registered Report Identifier (IRRID): DERR1-10.2196/65789
- 21 March 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e65789
Open AccessClinical Safety of Pudilan Xiaoyan Oral Liquid for the Treatment of Upper Respiratory Tract Infection in the Real World: Protocol for a Prospective, Observational, Registry Study
Background: Pudilan Xiaoyan oral liquid (PDL) is a proprietary Chinese medicine preparation widely used for upper respiratory tract infection, known for its significant therapeutic effects. However, the safety profiles reported in several observational studies vary, and these studies primarily focus on efficacy rather than specifically addressing safety concerns, thus representing inadequate safety monitoring. Objective: This study aimed to investigate the incidence of adverse drug reactions (ADRs) associated with PDL and explore the factors contributing to these reactions. Methods: The study is a prospective, observational, multicenter, hospital-based surveillance study. A total of 17 hospitals from China are involved. The study is expected to enroll a large sample of 10,000 patients aged between 18 and 80 years with upper respiratory tract infection who were prescribed PDL. The patients’ data, including demographics, medical history, diagnostic information, medication details, adverse events, and laboratory test results, will be monitored. The occurrence of ADRs will be recorded. The primary outcome is the incidence of ADR. Secondary outcomes are the ratio of patients whose body temperature return to the normal range (cases of body temperature normalization and the duration for achieving normal body temperature within a 3-day period will be documented) and changes in liver and kidney function (occurrence of drug-induced liver injury and acute kidney injury). Descriptive analyses will be performed for the primary and secondary outcomes. A cohort, nested, case-control study design will be used. If one patient has an ADR, then 4 patients without ADRs will be matched as the control group according to gender, age within 5 years, drug batch, and other factors, at a ratio of 1∶4 to compare the symptoms related to ADRs. The differences of ADR incidence among the possible influencing factors will be compared separately to find the factors with large differences. Then, synthetic minority oversampling technique and group least absolute shrinkage and selection operator methods will be used to identify factors influencing the occurrence of ADRs. Finally, propensity scoring methods will be used to control for confounding variables. The progress of each subcenter will be closely monitored, and the incidence of ADR will be systematically calculated. Furthermore, the characteristics and influencing factors of ADR will be analyzed, along with an investigation into its geographical distribution. Results: The study began on July 17, 2019. Due to the limited number of eligible patients, missed follow-ups, and the huge clinical burden caused by public health events in 2019, the final case will be enrolled on August 30, 2025. Conclusions: This study will obtain safety results of PDL in the real world and provide guidance on the clinical safety of traditional Chinese medicine formulations. Trial Registration: ClinicalTrials.gov NCT04031651; https://clinicaltrials.gov/study/NCT04031651 International Registered Report Identifier (IRRID): DERR1-10.2196/65789
- Open Access
- 5 December 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Access
- Vol. 12, 184629-184643
A Group Rotate-Vector Algorithm for Mixed-Variable Optimization Problems
Many engineering design optimization problems can be represented as mixed-variable optimization problems. This study presents a heuristic approach for solving mixed-variable optimization using rotation and contraction of vectors. The current optimization algorithm, known as rotate-vector, has shown promising results in solving optimization problems with real or integer variables. Building upon this concept, the authors of this paper develop methods to solve 0-1 type and general discrete type variables, and introduce corresponding rotation and contraction operators. To address the simultaneous search and optimization of multiple variable types in nonlinear mixed integer programming problems, a grouping and comprehensive processing method is employed. The proposed group rotate-vector algorithm (GRV) is evaluated through the solution of multiple 0-1 programming problems and mixed-variable optimization problems. The study also investigates the impact of parameter settings on solution quality and efficiency. The experimental results demonstrate that the GRV algorithm outperforms other algorithms in terms of solution quality.
- 5 December 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Access
- Vol. 12, 184629-184643
Open AccessA Group Rotate-Vector Algorithm for Mixed-Variable Optimization Problems
Many engineering design optimization problems can be represented as mixed-variable optimization problems. This study presents a heuristic approach for solving mixed-variable optimization using rotation and contraction of vectors. The current optimization algorithm, known as rotate-vector, has shown promising results in solving optimization problems with real or integer variables. Building upon this concept, the authors of this paper develop methods to solve 0-1 type and general discrete type variables, and introduce corresponding rotation and contraction operators. To address the simultaneous search and optimization of multiple variable types in nonlinear mixed integer programming problems, a grouping and comprehensive processing method is employed. The proposed group rotate-vector algorithm (GRV) is evaluated through the solution of multiple 0-1 programming problems and mixed-variable optimization problems. The study also investigates the impact of parameter settings on solution quality and efficiency. The experimental results demonstrate that the GRV algorithm outperforms other algorithms in terms of solution quality.
- Open Access
- 26 August 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Clinical Safety of Pudilan Xiaoyan Oral Liquid for the Treatment of Upper Respiratory Tract Infection in the Real World: Protocol for a Prospective, Observational, Registry Study (Preprint)
BACKGROUND Pudilan Xiaoyan oral liquid (PDL) is a proprietary Chinese medicine preparation widely used for upper respiratory tract infection, known for its significant therapeutic effects. However, the safety profiles reported in several observational studies vary, and these studies primarily focus on efficacy rather than specifically addressing safety concerns, thus representing inadequate safety monitoring. OBJECTIVE This study aimed to investigate the incidence of adverse drug reactions (ADRs) associated with PDL and explore the factors contributing to these reactions. METHODS The study is a prospective, observational, multicenter, hospital-based surveillance study. A total of 17 hospitals from China are involved. The study is expected to enroll a large sample of 10,000 patients aged between 18 and 80 years with upper respiratory tract infection who were prescribed PDL. The patients’ data, including demographics, medical history, diagnostic information, medication details, adverse events, and laboratory test results, will be monitored. The occurrence of ADRs will be recorded. The primary outcome is the incidence of ADR. Secondary outcomes are the ratio of patients whose body temperature return to the normal range (cases of body temperature normalization and the duration for achieving normal body temperature within a 3-day period will be documented) and changes in liver and kidney function (occurrence of drug-induced liver injury and acute kidney injury). Descriptive analyses will be performed for the primary and secondary outcomes. A cohort, nested, case-control study design will be used. If one patient has an ADR, then 4 patients without ADRs will be matched as the control group according to gender, age within 5 years, drug batch, and other factors, at a ratio of 1∶4 to compare the symptoms related to ADRs. The differences of ADR incidence among the possible influencing factors will be compared separately to find the factors with large differences. Then, synthetic minority oversampling technique and group least absolute shrinkage and selection operator methods will be used to identify factors influencing the occurrence of ADRs. Finally, propensity scoring methods will be used to control for confounding variables. The progress of each subcenter will be closely monitored, and the incidence of ADR will be systematically calculated. Furthermore, the characteristics and influencing factors of ADR will be analyzed, along with an investigation into its geographical distribution. RESULTS The study began on July 17, 2019. Due to the limited number of eligible patients, missed follow-ups, and the huge clinical burden caused by public health events in 2019, the final case will be enrolled on August 30, 2025. CONCLUSIONS This study will obtain safety results of PDL in the real world and provide guidance on the clinical safety of traditional Chinese medicine formulations. CLINICALTRIAL ClinicalTrials.gov NCT04031651; https://clinicaltrials.gov/study/NCT04031651 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/65789
- 26 August 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessClinical Safety of Pudilan Xiaoyan Oral Liquid for the Treatment of Upper Respiratory Tract Infection in the Real World: Protocol for a Prospective, Observational, Registry Study (Preprint)
BACKGROUND Pudilan Xiaoyan oral liquid (PDL) is a proprietary Chinese medicine preparation widely used for upper respiratory tract infection, known for its significant therapeutic effects. However, the safety profiles reported in several observational studies vary, and these studies primarily focus on efficacy rather than specifically addressing safety concerns, thus representing inadequate safety monitoring. OBJECTIVE This study aimed to investigate the incidence of adverse drug reactions (ADRs) associated with PDL and explore the factors contributing to these reactions. METHODS The study is a prospective, observational, multicenter, hospital-based surveillance study. A total of 17 hospitals from China are involved. The study is expected to enroll a large sample of 10,000 patients aged between 18 and 80 years with upper respiratory tract infection who were prescribed PDL. The patients’ data, including demographics, medical history, diagnostic information, medication details, adverse events, and laboratory test results, will be monitored. The occurrence of ADRs will be recorded. The primary outcome is the incidence of ADR. Secondary outcomes are the ratio of patients whose body temperature return to the normal range (cases of body temperature normalization and the duration for achieving normal body temperature within a 3-day period will be documented) and changes in liver and kidney function (occurrence of drug-induced liver injury and acute kidney injury). Descriptive analyses will be performed for the primary and secondary outcomes. A cohort, nested, case-control study design will be used. If one patient has an ADR, then 4 patients without ADRs will be matched as the control group according to gender, age within 5 years, drug batch, and other factors, at a ratio of 1∶4 to compare the symptoms related to ADRs. The differences of ADR incidence among the possible influencing factors will be compared separately to find the factors with large differences. Then, synthetic minority oversampling technique and group least absolute shrinkage and selection operator methods will be used to identify factors influencing the occurrence of ADRs. Finally, propensity scoring methods will be used to control for confounding variables. The progress of each subcenter will be closely monitored, and the incidence of ADR will be systematically calculated. Furthermore, the characteristics and influencing factors of ADR will be analyzed, along with an investigation into its geographical distribution. RESULTS The study began on July 17, 2019. Due to the limited number of eligible patients, missed follow-ups, and the huge clinical burden caused by public health events in 2019, the final case will be enrolled on August 30, 2025. CONCLUSIONS This study will obtain safety results of PDL in the real world and provide guidance on the clinical safety of traditional Chinese medicine formulations. CLINICALTRIAL ClinicalTrials.gov NCT04031651; https://clinicaltrials.gov/study/NCT04031651 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/65789